These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 8796286)

  • 1. Urokinase and non-urokinase fibrinolytic activity in protease-inhibitor-deprived plasma, assayed by a fibrin micro-plate method.
    Fossum S; Hoem NO
    Immunopharmacology; 1996 May; 32(1-3):119-21. PubMed ID: 8796286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus.
    Glas-Greenwalt P; Kant KS; Allen C; Pollak VE
    J Lab Clin Med; 1984 Dec; 104(6):962-76. PubMed ID: 6239000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different molecular forms of plasminogen and plasmin produced by urokinase in human plasma and their relation to protease inhibitors and lysis of fibrinogen and fibrin.
    Müllertz S
    Biochem J; 1974 Nov; 143(2):273-83. PubMed ID: 4282470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasminogen activator activity and plasma-coagulum lysis measured by use of optimized fibrin gel structure preformed in microtiter plates.
    Sidelmann J; Jespersen J; Gram J
    Clin Chem; 1995 Jul; 41(7):979-85. PubMed ID: 7541322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interfering factors in the assay of plasminogen activators by the fibrin plate method. Occurrence of different inhibitors against tissue plasminogen activator and urokinase.
    Wijngaards G
    Thromb Haemost; 1979 May; 41(3):590-600. PubMed ID: 111368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators.
    Sabovic M; Lijnen HR; Keber D; Collen D
    Thromb Haemost; 1989 Dec; 62(4):1083-7. PubMed ID: 2515603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Index of fibrinolysis with new fibrin plate (author's transl)].
    Hishikawa Y; Sugie I
    Nihon Seirigaku Zasshi; 1977; 39(1):1-11. PubMed ID: 140239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cleavage of surfactant-incorporating fibrin by different fibrinolytic agents. Kinetics of lysis and rescue of surface activity.
    Günther A; Markart P; Kalinowski M; Ruppert C; Grimminger F; Seeger W
    Am J Respir Cell Mol Biol; 1999 Dec; 21(6):738-45. PubMed ID: 10572071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitor of plasminogen activator in human arterial wall. II. Biochemical characterization.
    Okamura T; Nanno S; Sueishi K; Tanaka K
    Acta Pathol Jpn; 1984 Jul; 34(4):749-57. PubMed ID: 6237547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salivary fibrinolytic activity before and after oral surgery estimated on different types of fibrin.
    Gersel-Pedersin N
    Int J Oral Surg; 1976 Dec; 5(6):270-5. PubMed ID: 826490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasminogen activator content of human tumor and adjacent normal tissue measured with fibrin and non-fibrin assays.
    Camiolo SM; Greco WR
    Cancer Res; 1986 Apr; 46(4 Pt 1):1788-94. PubMed ID: 3081257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative study of the efficacy and specificity of tissue plasminogen activator and pro-urokinase: demonstration of synergism and of different thresholds of non-selectivity.
    Gurewich V; Pannell R
    Thromb Res; 1986 Oct; 44(2):217-28. PubMed ID: 3097872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemical coupling of a monoclonal antisurfactant protein-B antibody to human urokinase for targeting surfactant-incorporating alveolar fibrin.
    Ruppert C; Schmidt R; Grimminger F; Suzuki Y; Seeger W; Lehr CM; Günther A
    Bioconjug Chem; 2002; 13(4):804-11. PubMed ID: 12121136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained.
    Pannell R; Black J; Gurewich V
    J Clin Invest; 1988 Mar; 81(3):853-9. PubMed ID: 2963831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of fibrin-targeting on clot lysis with urokinase-type plasminogen activator.
    Lijnen HR; Dewerchin M; De Cock F; Collen D
    Thromb Res; 1990 Feb; 57(3):333-42. PubMed ID: 2107593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human C1-inhibitor prevents non-specific proteolysis by mutant pro-urokinase during optimal fibrinolysis.
    Gurewich V; Pannell R
    Thromb Haemost; 2009 Aug; 102(2):279-86. PubMed ID: 19652878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A miniaturized fibrinolytic assay for plasminogen activators.
    Lewis ML; Nachtwey DS; Damron KL
    Thromb Res; 1991 Oct; 64(2):223-34. PubMed ID: 1811341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secretion of fibrinolytic enzymes facilitates human mesenchymal stem cell invasion into fibrin clots.
    Neuss S; Schneider RK; Tietze L; Knüchel R; Jahnen-Dechent W
    Cells Tissues Organs; 2010; 191(1):36-46. PubMed ID: 19390164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of fibrinolysis by thrombospondin.
    Mosher DF; Misenheimer TM; Stenflo J; Hogg PJ
    Ann N Y Acad Sci; 1992 Dec; 667():64-9. PubMed ID: 1309073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole-blood fibrinolytic activity in normal and hypertensive pregnancies and its relation to the placental concentration of urokinase inhibitor.
    Arias F; Andrinopoulos G; Zamora J
    Am J Obstet Gynecol; 1979 Mar; 133(6):624-9. PubMed ID: 426017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.